Financial Comparison: Oncocyte (IMDX) & The Competition

Oncocyte (NASDAQ:IMDX) is one of 851 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Oncocyte to similar companies based on the strength of its analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

Oncocyte has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Oncocyte’s competitors have a beta of 1.11, meaning that their average share price is 11% more volatile than the S&P 500.

Valuation and Earnings

This table compares Oncocyte and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncocyte	$4.05 million	-$50.22 million	-2.31
Oncocyte Competitors	$737.67 million	$16.94 million	-10.46

Oncocyte’s competitors have higher revenue and earnings than Oncocyte. Oncocyte is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Oncocyte and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Oncocyte Competitors	-8,948.09%	-206.59%	-31.71%

Insider & Institutional Ownership

55.3% of Oncocyte shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology” companies are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Oncocyte and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Oncocyte Competitors	9463	14963	45008	1542	2.54

Oncocyte presently has a consensus price target of $10.50, indicating a potential upside of 205.23%. As a group, “Biotechnology” companies have a potential upside of 66.31%. Given Oncocyte’s higher probable upside, analysts clearly believe Oncocyte is more favorable than its competitors.

Summary

Oncocyte beats its competitors on 7 of the 13 factors compared.

Oncocyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.